Daiichi Sankyo Company, Limited announced the appointment of a new President & COO effective as of April 1, 2023, which was resolved at the Board of Directors meeting held on January 31. Reason for the appointment of new President & COO: company has positioned the first half of current 5-year Business Plan (5YBP, FY2021-FY2025) as a period for investment to maximize the value of 3 ADCs and have actively invested in R&D, supply chain, and oncology business capabilities. The company has made a very good progress in the 5YBP so far as the company successfully launched ENHERTU® and expanded its indications.

As a result, ENHERTU is rapidly gaining market share in countries and regions around the world. Other ADCs are also showing promising data. In the latter half of the 5YBP, the company are expecting to expand oncology business globally and enter into a period of profit growth.

To ensure that the company will achieve the 5YBP, the company need to enhance management structure, and in particular the execution of 5YBP strategies. The company appointed Sunao Manabe as Executive Chairperson and Hiroyuki Okuzawa as President & COO. Hiroyuki Okuzawa was Graduated from Hitotsubashi University (Faculty of Social Sciences).

Apr. 1986 Joined Sankyo Co. Ltd. Apr.

2017 Vice President, Business Planning Dept., ASCA Company of the Company. Apr. 2018 Corporate Officer, President, ASCA Company of the Company.

Apr. 2021 Executive Officer, Head of Corporate Planning & Management Div., CFO of the Company.